<DOC>
	<DOC>NCT00254995</DOC>
	<brief_summary>To further characterize the safety profile of Menactra vaccine and to identify any signals of potentially vaccine-related adverse events (AEs) not detected during pre-licensure studies.</brief_summary>
	<brief_title>Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Receipt of Menactra vaccine during the study period.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcal disease</keyword>
	<keyword>Menactra vaccine</keyword>
</DOC>